Baricitinib modulates the signaling pathway by preventing phosphorylation of JAKs and thereby inhibiting the STATs activation. and overcome the challenges associated with the absence of robust controlled studies. There is no established set of drugs to manage SARS-CoV-2 infected patients. However, closely following patients conditions and responding with the dosage guidelines of available drugs may significantly impact our ability to slow down the infection. Of note, it depends upon the condition of the patients and associated comorbid; therefore, the health workers need to choose the drug combinations judiciously until COVID-19 specific drug or vaccine is developed with the collective scientific rigor. In this article, we reviewed the available antimicrobial drug, supportive therapies, and probable high importance vaccines for the COVID-19 treatment. activity against SARS-CoV-2. However, there are minimal clinical evidence could be collected so far, and the efficacy of such drug therapies in the treatment of SARS-CoV-2 has not been established. The vaccines against COVID-19 will probably take at least a year to become available, and the use of available drugs to prevent disease (chemoprophylaxis) is the main option in hand for the management of infected patients. Therefore, for the management of the SARS-CoV-2, the current treatments are entirely supportive by nature. In general, pharmacological treatment is not suggested for young patients with mild indications CEACAM1 and without other underlying chronic conditions (Gao et?al., 2020). Figure 1 shows the life cycle of SARS-CoV-2 along with its possible inhibitors at various stages of its attachment, multiplication, and growth in the host cell. Available antimicrobials, adjunctive, supportive therapies, and probable vaccines are discussed in the following sections. Dugs and support therapies that are currently under clinical are listed in the Supplementary Material . Open in a separate window Figure 1 The life cycle of SARS-CoV-2 and its Trolox possible inhibitors. SARS-CoV-2 enters the target cells an endosomal pathway. The S protein binds with the angiotensin-converting enzyme 2 (ACE2) of the cell primed by serine protease TMPRSS2. Viral RNA is unveiled in the cytoplasm to produce PP1a and PP1ab polyproteins, which are Trolox cleaved to form nonstructural proteins. These non-structural proteins facilitate Trolox the formation of negative RNA by the process of replication and transcription. This, in turn, translates to N protein, another set of translation takes in the endoplasmic reticulum-ERGIC-Golgi to produce structural proteins (S, M, and E). Finally, the packing of viral RNA with N proteins and further assembly of S, M, and E proteins take place to form SARS-CoV-2 buds, which are released from the infected cell by exocytosis. Various drugs that are shown to inhibit the SARS-CoV-2 at various stages are CQ/HCQ, Chloroquine/Hydroxychloroquine; L, Lopinavir; R1, Ritonavir; I, Ivermectin; R, Remdesivir, R2, Resveratrol; D, Darunavir; C, Camostat. Antimicrobial Therapies Against COVID-19 Chloroquine Chloroquine ( Figure 2 ) has been used for years against malaria. This cost-effective and widely available therapeutic agent is also a robust antiviral, as it blocks a virus from invading the human cells. A large number of research groups are currently reviewing whether it effectively decreases the viral load in patients with SARS-CoV-2 (Savarino et?al., 2006; Marmor et?al., 2011; Cortegiani et?al., 2020). However, and limited scientific data indicate healing advantages against SARS-CoV-2 an infection. SARS-CoV-2 can be an enveloped trojan, and it enters the cell by endocytosis. Endocytosis is normally a cellular procedure in which components are taken in to the cell by causing a little vesicle. Once inside, a drop in pH promotes the fusion from the trojan envelope using the membrane from the vesicle that includes it, to become released in to the cytoplasm (McChesney, 1983). Right up until date, chloroquine is normally confirmed effective against COVID-19 through influencing bis (monoacylglycero) phosphate entrance by managing the endocytic pathway (Carrire et?al., 2020). The usage of chloroquine against COVID-19 could be a.